Navigation Links
Quest Diagnostics Wins Gold Medical Design Excellence Award (MDEA) for Diagnostic Innovation
Date:6/9/2011

MADISON, N.J., June 9, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Simplexa™ molecular diagnostic test on the 3M™ Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards ceremony yesterday in New York City. Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics, developed and provides the Simplexa™ line of molecular test products operating on the 3M Integrated Cycler as part of an exclusive global collaboration with 3M (MMM).

"Winning the MDEA award underscores our commitment to developing industry-leading diagnostics that will help physicians more effectively diagnose, treat and manage their patients," said Surya N. Mohapatra, Ph.D., chairman and chief executive officer, Quest Diagnostics. "We are particularly gratified to share this honor with our close collaborator 3M, a company which shares our enthusiasm for developing breakthrough technologies that help improve patient care."

The MDEA competition recognizes advances in the design of medical products. Presented by UBM Canon, MDEA award winners are selected by an impartial jury on criteria that include design and engineering features that improve healthcare delivery, innovative use of materials and components, and functional innovations that change traditional medical attitudes or practices or offer significant use-related improvements.

In April 2011, the Simplexa/3M technology won a bronze 2011 Edison Award for new science and medical diagnostic product, based on criteria that included technological innovation and marketplace success.

Focus Diagnostics launched the Simplexa molecular product line in 2009. Simplexa was the first test kit to be FDA cleared for aiding in the detection and differentiation of the 2009 H1N1 influenza virus, in May 2010. Additional FDA cleared Simplexa tests aid the detection of influenza A and B and respiratory syncthial virus. Several other Simplexa branded tests, including for Clostridium difficile, Epstein Barr and BK viruses, are CE marked and distributed in Europe. Simplexa tests run on the 3M Integrated Cycler, a compact, portable testing platform which can provide test results in as few as 60 minutes.

"We designed our Simplexa test to serve the unmet need for fast, high quality testing that hospitals and other healthcare facilities can perform near their patients," said John G. Hurrell, Ph.D., vice president and general manager, Focus Diagnostics. "A fast, reliable test result is essential to effective treatment for many diseases. The MDEA and Edison Awards highlight the importance of the Simplexa and 3M products in helping physicians to make well informed and timely clinical decisions for their patients."

About Focus Diagnostics

Focus Diagnostics, Inc. is an infectious disease diagnostics company, providing infectious disease reference laboratory services to hospitals and laboratories nationwide, and manufacturing and distributing diagnostic products worldwide. Focus Diagnostics develops innovative tests and products to assist physicians in diagnosing infectious diseases, and often provides the first diagnostic tests in the U.S. for emerging diseases, such as West Nile virus and SARS. HerpeSelect® type-specific HSV serology and West Nile Virus DxSelect™ are top-selling Focus Diagnostics products used in laboratories worldwide. Focus Diagnostics is a wholly owned subsidiary of Quest Diagnostics. Visit FocusDx.com or Simplexa.com.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. For more information, refer to QuestDiagnostics.com.

Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.

Contacts:
Wendy Bost (Media): 973-520-2800
Kathleen Valentine (Investors): 973-520-2900


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics to Speak at the Jefferies 2011 Global Healthcare Conference
2. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
3. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
4. Quest Diagnostics Successfully Completes Acquisition of Celera
5. Quest Diagnostics Declares Quarterly Cash Dividend
6. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
7. Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger
8. Quest Diagnostics Sponsors American Cancer Societys Choose You® Movement
9. Quest Diagnostics Announces Final Extension of Subsequent Offering Period for Shares of Celera
10. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
11. Quest Diagnostics Launches Simplexa™ C. Difficile Universal Direct Test in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):